The 9p21 locus: A potential therapeutic target and prognostic marker in breast cancer

2018 ◽  
Vol 233 (7) ◽  
pp. 5170-5179 ◽  
Author(s):  
Mahdi Rivandi ◽  
Mohammad-Sadegh Khorrami ◽  
Hamid Fiuji ◽  
Soodabeh Shahidsales ◽  
Malihe Hasanzadeh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Marker ◽  
Therapeutic Target ◽  
Potential Therapeutic Target ◽  
9P21 Locus

The 9p21 locus as a potential therapeutic target and prognostic marker in colorectal cancer

2018 ◽  
Vol 19 (5) ◽  
pp. 463-474 ◽  
Author(s):  
Afsane Bahrami ◽  
Seyed Mahdi Hassanian ◽  
Majid Khazaei ◽  
Masoumeh Gharib ◽  
Mahsa Rahmani ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Marker ◽  
Therapeutic Target ◽  
Potential Therapeutic Target ◽  
9P21 Locus

RUNX3 is a prognostic marker and potential therapeutic target in human breast cancer

2013 ◽  
Vol 139 (11) ◽  
pp. 1813-1823 ◽  
Author(s):  
Jin Bai ◽  
Hong-Mei Yong ◽  
Fei-Fei Chen ◽  
Wen-Bo Song ◽  
Chen Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Marker ◽  
Therapeutic Target ◽  
Human Breast Cancer ◽  
Human Breast ◽  
Potential Therapeutic Target

scholarly journals BRG1 Is a Prognostic Marker and Potential Therapeutic Target in Human Breast Cancer

PLoS ONE ◽  
2013 ◽  
Vol 8 (3) ◽  
pp. e59772 ◽  
Author(s):  
Jin Bai ◽  
Pengjin Mei ◽  
Cuipeng Zhang ◽  
Feifei Chen ◽  
Chen Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Marker ◽  
Therapeutic Target ◽  
Human Breast Cancer ◽  
Human Breast ◽  
Potential Therapeutic Target

scholarly journals Ghrelin is a prognostic marker and a potential therapeutic target in breast cancer

PLoS ONE ◽  
2017 ◽  
Vol 12 (4) ◽  
pp. e0176059 ◽  
Author(s):  
Malin Grönberg ◽  
Cecilia Ahlin ◽  
Ylva Naeser ◽  
Eva Tiensuu Janson ◽  
Lars Holmberg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Marker ◽  
Therapeutic Target ◽  
Potential Therapeutic Target

scholarly journals O28: M6A DEMETHYLASE FTO A POTENTIAL TARGET IN BRAIN METASTATIC BREAST CANCER

2021 ◽  
Vol 108 (Supplement_1) ◽  
Author(s):  
S Keelan ◽  
S Charmsaz ◽  
S Purcell ◽  
D Varešlija ◽  
S Cocchiglia ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Brain Metastasis ◽  
Disease Progression ◽  
Therapeutic Target ◽  
Disease Free Survival ◽  
Metastatic Breast ◽  
Potential Therapeutic Target ◽  
Rna Methylation ◽  
Pharmacological Inhibition

Abstract Introduction Brain metastasis (BrM) occurs in 10-30% of patients with advanced breast cancer (BC). BrM is increasing in incidence and confers a poor prognosis. We aimed to investigate the contribution of global epi-transcriptomic alterations in N6-methyladenosine (m6A) RNA-methylation as a therapeutic target in brain metastatic breast cancer. Method In preliminary studies we have demonstrated m6A demethylase – FTO as the main contributor to the progression of ER+ breast cancer. Furthermore an association between FTO and reduced disease-free-survival (n=870, p=0.018) was observed. Here we conducted an epigenetic inhibitor screen using two therapeutic agents, ethyl-ester-meclofenamic acid (MA2) and FB23-2 on matched 2D cell line, 3D organoid cultures and patient-derived xenografts (PDX) explant models of brain metastasis. Result Upon integration of mapped global RNA methylation landscape with matched proteomic analysis, we observed genome-wide RNA hypo-methylation of key pluripotency genes, including SOX2 and KLF4, as key players underlying tumour progression to the brain.  Genetic and pharmacological inhibition of FTO in novel ex vivo models of BrM significantly reduced protein expression levels of KLF4 and SOX2. Moreover, pharmacological inhibition of FTO with MA2 and FB23-2, inhibited cell proliferation in endocrine-resistant BC and patient BrM cells. We translate our findings to the clinic by demonstrating the efficacy of anti-FTO therapies in several unique PDX and 3D organoid BrM models. Conclusion Our results reveal epi-transcriptional remodelling events as a key mechanism in BrM. This study establishes an early role for targeting RNA methylation in the management of disease progression and presents FTO as a potential therapeutic target in BrM. Take-home message This study establishes an early role for targeting RNA methylation in the management of disease progression and presents FTO as a potential therapeutic target in brain metastatic breast cancer.

scholarly journals Stromal cells in breast cancer as a potential therapeutic target

Oncotarget ◽  
2018 ◽  
Vol 9 (34) ◽  
pp. 23761-23779 ◽  
Author(s):  
Samantha S. Dykes ◽  
Veronica S. Hughes ◽  
Jennifer M. Wiggins ◽  
Henrietta O. Fasanya ◽  
Mai Tanaka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stromal Cells ◽  
Therapeutic Target ◽  
Potential Therapeutic Target

scholarly journals FoxM1 is an independent poor prognostic marker and therapeutic target for advanced Middle Eastern breast cancer

Oncotarget ◽  
2018 ◽  
Vol 9 (25) ◽  
pp. 17466-17482 ◽  
Author(s):  
Abdul Khalid Siraj ◽  
Poyil Pratheeshkumar ◽  
Sandeep Kumar Parvathareddy ◽  
Zeeshan Qadri ◽  
Saravanan Thangavel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Marker ◽  
Therapeutic Target ◽  
Middle Eastern

c-Met as a potential therapeutic target in triple negative breast cancer

2020 ◽  
pp. 295-326
Author(s):  
Sapana Sameer Chaudhary ◽  
Sameer Choudhary ◽  
Sakshi Rawat ◽  
Gouri Ahir ◽  
Anwar L. Bilgrami ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Therapeutic Target ◽  
Triple Negative ◽  
Potential Therapeutic Target
Sign in / Sign up

Export Citation Format

Share Document